Latest Stories
Letter To The Editor
I was disappointed to see that you reported on the results of the IMpassion 131 trial, without context. [The Cancer Letter, Sept. 4, 2020]
FreeGuest Editorial
Breast cancer research is big business. And the incentives in that business are designed to benefit industry, doctors and institutions, leaving patients behind. In 2018 alone, about $1 billion federal dollars were invested in institutions around the country to fund research.